Biogen
About Biogen
Biogen is a pioneer in neuroscience headquartered in Cambridge, Massachusetts, developing therapies for neurological and neurodegenerative diseases including multiple sclerosis and Alzheimer's.
Milestones
Milestones as listed on biogen.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Leadership Team
Leadership as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Rachid Izzar
Products & Services
Products and services as listed on biogen-uk-ie.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
LEQEMBI (lecanemab)
Listed on Biogen's UK & Ireland medicines page.
Source: biogen-uk-ie.comSPINRAZA (nusinersen sodium)
Listed on Biogen's UK & Ireland medicines page.
Source: biogen-uk-ie.comTYSABRI (natalizumab)
Listed on Biogen's UK & Ireland medicines page.
Source: biogen-uk-ie.comVUMERITY (diroximel fumarate)
Listed on Biogen's UK & Ireland medicines page.
Source: biogen-uk-ie.comQALSODY (tofersen)
Listed on Biogen's UK & Ireland medicines page.
Source: biogen-uk-ie.comSKYCLARYS (omavoloxelone)
Listed on Biogen's UK & Ireland medicines page.
Source: biogen-uk-ie.comZURZUVAE (zuranolone)
Listed on Biogen's UK & Ireland medicines page.
Source: biogen-uk-ie.comBENEPALI (etanercept)
Listed on Biogen's UK & Ireland medicines page.
Source: biogen-uk-ie.comSites in Ireland
Sites as listed on biogen-uk-ie.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Pipeline & Regulatory Record
What public registers list for Biogen: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 22 Nov 2026.
Clinical trials 38 in our ClinicalTrials.gov registers · 3 in the EU register
Showing 10 of 38, trials with Irish sites first. The full lists are on the sponsor pages below.
All trials by sponsor name 2 registry names
Drugs in these trials 14 compounds
EU trials register (CTIS) 3 authorised or ongoing · 2 in Ireland
- A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants with Genetically Diagnosed Spinal Muscular Atrophy2025-523857-32-00 · Phase III · Authorised · site in Ireland
- An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam2025-524054-34-00 · Phase III · Authorised · site in Ireland
- A Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adult Participants with Graves’ Disease2026-526482-19-00 · Phase II · Authorised
NICE technology appraisals 8 of its medicines · 8 current
- Nusinersen and risdiplam for treating spinal muscular atrophyNICE TA1162 · Recommended, Optimised · 4 Jun 2026
- Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapyNICE TA1126 · Optimised, Not recommended · 28 Jan 2026
- Omaveloxolone for treating Friedreich’s ataxia in people 16 years and over (terminated appraisal)NICE TA1061 · Terminated (no company submission) · 6 May 2025
- Diroximel fumarate for treating relapsing–remitting multiple sclerosisNICE TA794 · Optimised · 8 Jun 2022
- Peginterferon beta-1a for treating relapsing–remitting multiple sclerosisNICE TA624 · Recommended · 19 Feb 2020
- Beta interferons and glatiramer acetate for treating multiple sclerosisNICE TA527 · Recommended, Not recommended · 27 Jun 2018
- Dimethyl fumarate for treating relapsing‑remitting multiple sclerosisNICE TA320 · Recommended · 27 Aug 2014
- Natalizumab for treating rapidly evolving severe relapsing–remitting multiple sclerosisNICE TA127 · Optimised · 22 Aug 2007
Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Group (Biogen): founded 1978, headquarters Cambridge, website biogen.com. Wikidata Q864338 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.
How this is matched: register records are linked to this page by the organisation name they carry, here Biogen; Biogen Idec Research Limited; Biogen Netherlands B.V.; BIOGEN IDEC; BIOGEN; Biogen Netherlands B.V. and 2 more. Spot a wrong match? Tell us.
Financials & Irish Entities
From the annual reports Biogen Inc. files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $9.89bn | $1.78bn | 18.0% | $1.29bn | 10-K 2026 |
| Dec 2024 | $9.68bn | $1.98bn | 20.5% | $1.63bn | 10-K 2026 |
| Dec 2023 | $9.84bn | $2.45bn | 24.9% | $1.16bn | 10-K 2026 |
| Dec 2022 | $10.17bn | $2.23bn | 21.9% | $3.05bn | 10-K 2025 |
| Dec 2021 | $10.98bn | $2.50bn | 22.8% | $1.56bn | 10-K 2024 |
R&D is shown as tagged in the filing, which for this company can exclude acquired in-process R&D. Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.
Companies registered in Ireland 2 active in the CRO register
| Company | CRO no. | Registered | Last accounts |
|---|---|---|---|
| Biogen Idec (Ireland) Limited LTD - Private Company Limited by Shares | 421718 | 2006 | Dec 2025 |
| Biogen Distribution Services Limited LTD - Private Company Limited by Shares | 689062 | 2021 | Dec 2025 |
From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Biogen Inc. as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.